**Supplementary Table 1. Patients’ subjective bladder condition (full analysis set)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Placebo****(N=72)** | **DA-8010 2.5mg****(N=70)** | **DA-8010 5mg****(N=71)** | **Solifenacin 5mg****(N=72)** |
| **Patient Perception of Bladder Condition (PPBC)** |  |  |  |  |
| **Baseline** | 3.83±1.13[4.00] | 4.00±1.02[4.00] | 3.89±1.21[4.00] | 3.74±1.22[4.00] |
| **Change from Baseline at Week 4** | -0.60±1.15[0.00] | -0.71±1.07[-1.00] | -0.76±1.35[-1.00] | -0.65±1.20[-1.00] |
|  LS Mean(SE) | -0.61(0.13) | -0.64(0.13) | -0.74(0.13) |  |
|  P-value [1] | 　 | 0.8782 | 0.4576 | 　 |
| **Change from Baseline at Week 8** | -0.76±1.28[-1.00] | -0.80±1.00[-1.00] | -0.82±1.09[-1.00] | -0.71±1.29[-1.00] |
|  LS Mean(SE) | -0.78(0.13) | -0.75(0.13) | -0.81(0.13) |  |
|  P-value [1] | 　 | 0.8733 | 0.8625 | 　 |
| **Change from Baseline at Week 12** | -0.67±1.28[-1.00] | -1.06±1.08[-1.00] | -0.92±1.09[-1.00] | -0.79±1.39[-1.00] |
|  LS Mean(SE) | -0.64(0.13) | -0.96(0.13) | -0.86(0.13) |  |
|  P-value [1] | 　 | 0.0802 | 0.2234 | 　 |
| **Overactive Bladder Questionnaire (OAB-q) Symptom Severity** |  |  |  |  |
| **Baseline** | 44.68±22.76[40.00] | 41.90±19.68[36.67] | 45.40±20.18[43.33] | 43.10±23.20[40.00] |
| **Change from Baseline at Week 4** | -8.98±17.35[-6.67] | -9.71±18.15[-10.00] | -13.57±17.57[-13.33] | -13.29±16.61[-13.33] |
|  P-value [2] | 　 | 0.3770 | 0.0917 | 　 |
| **Change from Baseline at Week 12** | -14.31±24.47[-10.00] | -16.19±17.43[-16.67] | -18.26±17.63[-16.67] | -14.86±18.81[-13.33] |
|  P-value [2] | 　 | 0.0640 | 0.0942 | 　 |
| **OAB-q - Total health-related quality of life (HRQL) Score** |  |  |  |  |
| **Baseline** | 59.42±19.44[58.46] | 61.98±19.95[63.08] | 61.37±20.80[64.62] | 64.23±20.06[61.54] |
| **Change from Baseline at Week 4** | 8.63±16.71[7.69] | 7.01±14.40[6.15] | 9.77±15.10[9.23] | 8.61±14.08[8.46] |
|  P-value [2] | 　 | 0.9824 | 0.3609 | 　 |
| **Change from Baseline at Week 12** | 13.65±21.36[10.77] | 12.81±17.12[10.77] | 15.10±18.05[13.85] | 11.79±15.16[10.77] |
|  P-value [2] | 　 | 0.6214 | 0.3099 | 　 |

LS mean=least square mean; SE=standard error

The values are expressed as mean ± standard deviation [median] or LS mean (SE)

The results of the solifenacin 5mg group were added for exploratory analysis

[1] ANCOVA model with adjustment for the baseline value and gender for the comparison of DA-8010 2.5 mg, 5 mg vs. Placebo

[2] Rank-ANCOVA model with adjustment for the baseline value and gender for the comparison of DA-8010 2.5 mg, 5 mg vs. Placebo